About the Startup
Clinical-stage biotech developing next-generation DNA damage response (DDR) cancer therapies, including ATR inhibitor alnodesertib and Polθ inhibitor ART6043, plus preclinical DDRi-ADCs.
Frequently Asked Questions
What type of funding round did Artios raise?
Artios raised a series-d round.
How much did Artios raise in its series-d?
Artios raised $115,000,000 USD in its series-d.
Who invested in Artios's series-d?
The investors in Artios's series-d are: SV Health Investors, RA Capital Management, Janus Henderson Investors, Andera Partners, Avidity Partners, EQT Life Sciences, Invus, IP Group plc, M Ventures, Novartis Venture Fund, Omega Funds, Pfizer Ventures, Piper Heartland, Sofinnova Partners, Schroders Capital.
What type of investment was Artios's series-d?
Artios's series-d was a equity investment.